NORTHBROOK, Ill. -- (BUSINESS WIRE) -- Marathon Pharmaceuticals, LLC today announced Babar Ghias has joined the company as vice president of corporate development.
Ghias, 35, most recently served as Director for Credit Suisse’s Mergers & Acquisitions Group in New York, where he led completion of more than $80 billion in transactions for small and large-cap client companies, primarily in the global healthcare sector.
As part of Marathon’s executive team, Ghias is responsible for identifying and evaluating business development opportunities, deal structuring, financial strategy and managing Marathon’s capital structure. In addition, he will proactively create beneficial relationships with private equity players, pharmaceutical companies, and investment bankers.
“Babar’s expertise in creatively executing deals will be very valuable to Marathon as it builds its portfolio of treatments for rare diseases. His work is integral to fulfilling our mission to deliver novel therapies to patients who currently have none,” said Jeffrey Aronin, Marathon Pharmaceuticals’ CEO.
Ghias holds an MBA from Washington University in St. Louis, and a Bachelor’s Degree in economics from Lahore University of Management Sciences in Pakistan. Early in his career, he was an analyst for the Investment Banking Group at UBS Securities in Pakistan.
Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases and makes small volume, hard-to-manufacture medications available to people who need them. Marathon is focused on providing medicine to patients who currently have no treatment options. The company manufactures prescription medications and is developing a pipeline of treatments for rare cancers and neurological disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago and New Jersey. For more information visit www.marathonpharma.com.